What renal tubular disorders present in adolescents, and what are their typical clinical features, diagnostic workup, and first‑ and second‑line treatments?

Renal Tubular Disorders Presenting in Adolescence

Bartter syndrome type 3 and Gitelman syndrome are the primary renal tubular disorders presenting in adolescence, with Bartter type 3 manifesting between ages 0-5 years and often into adolescence, while distal renal tubular acidosis can also present with delayed diagnosis in this age group 1.

Key Disorders and Clinical Presentations

Bartter Syndrome Type 3

This is the most common tubular disorder presenting beyond infancy into adolescence 1. The clinical presentation includes:

• Polyuria and polydipsia as leading symptoms
• Hypokalemic metabolic alkalosis with hypochloremia
• Variable calcium excretion (unlike types 1,2,4, and 5 which have consistently high calcium excretion)
• Hypomagnesemia may be present
• Hypocalciuria or normal calcium excretion distinguishes it from other Bartter types
• Features can be virtually indistinguishable from Gitelman syndrome 1

Gitelman Syndrome

Adolescents with hypocalciuria and/or hypomagnesemia presenting with metabolic alkalosis should be evaluated for Gitelman syndrome 1. This disorder affects the distal convoluted tubule and shares clinical features with Bartter type 3.

Distal Renal Tubular Acidosis (dRTA)

Adolescents may present with nephrocalcinosis, kidney stones, short stature, or growth failure 1, 2, 3. Key features include:

• Normal anion gap metabolic acidosis with hypokalemia and hyperchloremia
• Persistently alkaline urine (pH >7.0) despite systemic acidosis
• Nephrocalcinosis and/or urolithiasis as presenting signs
• Growth retardation and skeletal abnormalities
• Sensorineural deafness in specific genetic subtypes (ATP6V1B1, ATP6V0A4 mutations) 4, 5

Diagnostic Workup Algorithm

Initial Laboratory Assessment

When an adolescent presents with unexplained weakness, growth failure, or recurrent kidney stones:

1. Serum electrolytes with calculated anion gap

   • Metabolic alkalosis → consider Bartter/Gitelman
   • Normal anion gap acidosis → consider dRTA

2. Serum potassium, magnesium, calcium, phosphate

3. Venous blood gas to confirm acid-base status

4. Urinary studies:

   • Fractional chloride excretion >0.5% indicates renal salt wasting in Bartter syndrome 1
   • Urinary pH - persistently >5.5 despite acidosis confirms dRTA
   • 24-hour urine for calcium - hypercalciuria in most Bartter types; hypocalciuria suggests Bartter type 3 or Gitelman
   • Urinary sodium/chloride ratio to distinguish renal from extrarenal losses

5. Renal ultrasound to identify nephrocalcinosis (common in dRTA and some Bartter types)

Exclude Secondary Causes

Before diagnosing inherited tubulopathy, exclude:

• Diuretic or laxative abuse (particularly important in adolescents)
• Primary hyperaldosteronism
• Cystic fibrosis (pseudo-Bartter from sweat losses) 1
• Autoimmune diseases (acquired dRTA)

Genetic Testing

Genetic analysis has superseded functional tubular testing and should be pursued once clinical diagnosis is suspected 1.

For Bartter syndrome, test: SLC12A1, KCNJ1, CLCNKB, CLCNKA, BSND, MAGED2 1

For dRTA, test: SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, WDR72 5

Important caveat: Avoid routine diuretic challenge tests - they are obsolete and carry risk of severe volume depletion, especially with compensatory upregulation in distal tubule 1.

First-Line Treatment

Bartter Syndrome

The cornerstone of treatment combines electrolyte supplementation with NSAIDs 1:

1. Sodium chloride supplementation - adjusted to symptoms and severity
2. Potassium chloride supplementation - to correct hypokalemia
3. Liberal fluid intake to compensate for polyuria
4. NSAIDs (primarily indomethacin) - mainstay during first years, blocks prostaglandin-mediated renin secretion 1

Dosing is individualized based on:

• Severity of tubulopathy
• Age of patient
• Glomerular filtration rate
• Symptom control and tolerability

Distal Renal Tubular Acidosis

Alkali therapy is the definitive first-line treatment 5:

1. Potassium citrate or potassium bicarbonate - corrects both acidosis and hypokalemia
2. Sodium bicarbonate or sodium citrate - alternative alkali source
3. Target serum bicarbonate >22 mEq/L to prevent complications
4. ADV7103 (extended-release potassium citrate/bicarbonate) - recently approved by EMA, offers improved adherence with less frequent dosing 5

Additional supplementation:

• Vitamin D and calcium if deficient
• Phosphate if hypophosphatemia present

Second-Line and Adjunctive Therapies

For Bartter Syndrome

Evidence for these therapies is limited but they may be considered 1:

• Potassium-sparing diuretics (amiloride, spironolactone)
• ACE inhibitors or ARBs - may reduce potassium wasting
• Magnesium supplementation when hypomagnesemia present

Critical warning: Long-term NSAID use carries risk of chronic kidney disease progression, though definitive evidence is lacking 1.

For Distal RTA

• Thiazide diuretics - may reduce hypercalciuria and stone formation
• Citrate supplementation - provides both alkali and stone prevention

Monitoring and Long-Term Outcomes

Regular monitoring should include:

• Growth parameters - height velocity, bone age
• Serum electrolytes and acid-base status - every 3-6 months
• Renal function (eGFR) - annually or more frequently if declining
• Renal ultrasound - monitor nephrocalcinosis progression
• Audiometry - for dRTA patients with ATP6V1B1/ATP6V0A4 mutations 4, 5

Long-term complications to anticipate:

• 32% develop eGFR <90 mL/min/1.73m² in primary tubulopathies 4
• Sensorineural deafness in 75% of dRTA patients with specific mutations 4
• Metabolic decompensations requiring hospitalization
• Nephrolithiasis and renal colic
• Growth impairment - largely reversible with adequate treatment 4

Critical Clinical Pearls

When hypokalemia is the presenting sign in an adolescent:

1. Distinguish renal from GI losses using urinary chloride
2. Exclude diuretic/laxative abuse before pursuing genetic diagnosis
3. Fractional chloride excretion >0.5% confirms renal wasting 1

When kidney stones present in adolescence:

• Young age at stone onset mandates evaluation for underlying tubulopathy
• Consider incomplete dRTA even without overt acidosis 1

Bartter type 3 vs Gitelman distinction:

• Hypocalciuria favors Gitelman or Bartter type 3
• Hypercalciuria favors other Bartter types
• Genetic testing provides definitive diagnosis 1